Pure Global

The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects - Trial NCT03903081

Access comprehensive clinical trial information for NCT03903081 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sunshine Lake Pharma Co., Ltd. and is currently Completed. The study focuses on Chronic Hepatitis C. Target enrollment is 93 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT03903081
Phase 1
Completed
drug
Trial Details
ClinicalTrials.gov • NCT03903081
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects
A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single & Multiple Ascending Dose Study to Access the Tolerability and Pharmacokinetics of HEC110114 Tablets in Healthy Adult Subjects

Study Focus

Chronic Hepatitis C

HEC110114 tablet

Interventional

drug

Sponsor & Location

Sunshine Lake Pharma Co., Ltd.

Changchun, China

Timeline & Enrollment

Phase 1

Mar 06, 2019

Oct 29, 2019

93 participants

Primary Outcome

Adverse Events

Summary

A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single & Multiple
 Ascending Dose Study to Access the Tolerability and Pharmacokinetics of HEC110114 Tablets in
 Healthy Adult Subjects

ICD-10 Classifications

Chronic viral hepatitis C
Acute hepatitis C
Chronic viral hepatitis
Other chronic viral hepatitis
Chronic hepatitis, unspecified

Data Source

ClinicalTrials.gov

NCT03903081

Non-Device Trial